No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects.
Peptides
; 125: 170176, 2020 03.
Article
em En
| MEDLINE
| ID: mdl-31669136
ABSTRACT
BACKGROUND, AIMS:
In patients with type 2 diabetes, the lost insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) is more apparent after continuous versus bolus administration. To test whether the difference might be explained by rapid tachyphylaxis in response to elevated concentrations of GIP, and whether patients with type 2 diabetes and their relatives are more susceptible to tachyphylaxis than healthy subjects. PATIENTS ANDMETHODS:
In a two-way crossover design, insulinotropic responses to repeated bolus injection (50â¯pmol/kg body weight at 30 and 120â¯min) and continuous infusion of GIP (2â¯pmol.kg-1.min-1 from 30 to 180â¯min) under hyperglycaemic clamp conditions (8.5â¯mmol/l) was compared in age- gender- and weight-matched patients with type 2 diabetes, first degree relatives of such patients, and healthy subjects.RESULTS:
Insulin secretory responses to the first and second GIP bolus were not significantly different in any of the subject groups. Subjects with type 2 diabetes had a significant relative impairment versus healthy subjects with continuous (C-peptide, -13.2 %, pâ¯<â¯0.05), but not with repeated bolus administration of GIP (+11.1 %, n.s.). First-degree relatives tended to hyper-secrete insulin with bolus or continuous administrations of GIP.CONCLUSIONS:
Rapid tachyphylaxis in response to continuous exposure to slightly supraphysiological concentrations of GIP does not explain the reduced insulinotropic response to GIP infusions in patients with type 2 diabetes or their first-degree relatives.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Taquifilaxia
/
Receptores dos Hormônios Gastrointestinais
/
Fármacos Gastrointestinais
/
Polipeptídeo Inibidor Gástrico
/
Diabetes Mellitus Tipo 2
/
Secreção de Insulina
Tipo de estudo:
Observational_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Peptides
Ano de publicação:
2020
Tipo de documento:
Article